Patent: 6,399,061
✉ Email this page to a colleague
Summary for Patent: 6,399,061
Title: | Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma |
Abstract: | Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119. |
Inventor(s): | Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA) |
Assignee: | IDEC Pharmaceutical Corporation (San Diego, CA) |
Application Number: | 08/475,815 |
Patent Claims: | see list of patent claims |
Details for Patent 6,399,061
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Acrotech Biopharma Inc. | ZEVALIN | ibritumomab tiuxetan | Injection | 125019 | February 19, 2002 | ⤷ Sign Up | 2019-06-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,399,061
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | E139900 | ⤷ Sign Up |
Austria | E196606 | ⤷ Sign Up |
Austria | E421335 | ⤷ Sign Up |
Austria | E431158 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |